Palmitate and Insulin Release: The Role of GPR40 and Rosiglitazone
Author Information
Author(s): Meidute Abaraviciene, Sandra Lundquist, Ingmar Galvanovskis, Erik Flodgren, Björn Olde, Albert Salehi
Primary Institution: Malmö University Hospital, Malmö, Sweden
Hypothesis
The study investigates the effects of palmitate on pancreatic islet function and the role of GPR40 and rosiglitazone in insulin release.
Conclusion
The adverse effects of palmitate on insulin release are counteracted by rosiglitazone, suggesting its potential benefits for β-cell function in type 2 diabetes.
Supporting Evidence
- Rosiglitazone suppressed palmitate-stimulated insulin release in cultured cells.
- Palmitate increased iNOS expression and NO production in pancreatic islets.
- Downregulation of GPR40 reduced palmitate-induced iNOS activity and insulin release.
Takeaway
When the body has too much fat, it can hurt the cells that make insulin. A medicine called rosiglitazone can help these cells work better again.
Methodology
The study used HEK293 and MIN6c4 cells to assess the effects of palmitate and rosiglitazone on insulin release and nitric oxide synthase activities.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website